July 25, 2024

Cancer Minimal Residual Disease Testing Market is poised to witness trends in digital biomarker monitoring by the rising adoption of AI-powered diagnostics

MRD testing utilizes highly sensitive techniques such as next-generation sequencing and polymerase chain reaction to detect the presence of cancer cells at the molecular or genomic level during remission after initial therapy. This helps monitor treatment response in hematological and solid tumor cancers and optimize therapeutic strategies.

The global cancer MRD testing market is estimated to be valued at US$ 2.31 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.

Key players operating in the cancer MRD testing market are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc. These players are focused on developing and commercializing highly sensitive platforms such as next-generation sequencing, digital PCR, and multi-omics technologies for liquid biopsy-based cancer MRD testing.

Key Takeaways

Key players: Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc. are focused on developing and commercializing highly sensitive platforms such as next-generation sequencing, digital PCR, and multi-omics technologies for liquid biopsy-based cancer MRD testing.

Growing demand: The widespread adoption of precision medicine and liquid biopsy technologies are propelling the demand for cancer MRD testing. Minimal Residual Disease Testing Market Demand is gaining prominence for improving clinical outcomes and tailoring personalized treatment regimens.

Global expansion: Leading market players are focusing on geographical expansion strategies to strengthen their global presence. Partnerships with healthcare providers, labs, biobanks, and research institutes are helping drive the global availability of cancer MRD testing solutions.

Market Key Trends

The cancer MRD testing market is witnessing a growing trend of digital biomarker monitoring with the rising adoption of AI-powered diagnostics. Companies are developing assays and platforms that integrate multi-omics data processing, deep learning algorithms, and cloud-based software for automated MRD detection and real-time treatment monitoring. Digital biomarkers obtained from liquid biopsies can transform cancer management by enabling remote patient monitoring and providing real-time insights to guide precision therapies. This convergence of MRD testing with AI and digital technologies is likely to reshape the treatment landscape for various cancers going forward.

Porter’s Analysis
Threat of new entrants: Minimal Residual Disease Testing requires high capital investment and strict regulatory guidelines which discourage new players to enter the market.
Bargaining power of buyers: Large healthcare organizations and hospitals have high bargaining power as buyers due to their ability to choose from many test providers and demand value additions.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to differentiated technology platforms and reagents used in Minimal Residual Disease Testing.
Threat of new substitutes: No close substitutes exist for Minimal Residual Disease Testing as it plays a vital role in cancer prognosis and management.
Competitive rivalry: The market is dominated by few leading players and faces moderate-high competitive rivalry.

Geographical Regions

North America currently holds the largest share of the Minimal Residual Disease Testing market in terms of value owing to the presence of major market players, healthcare reimbursements, and growing cancer incidence.
The Asia Pacific region is expected to witness the fastest growth during the forecast period due to improving healthcare infrastructure, rising awareness, and growing medical tourism. Countries like China, India, and Japan are expected to be the major revenue contributors.

*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it